Nutlin-3a, a novel small-molecule inhibitor of the p53-MDM2 interaction, has been shown to be highly effective in killing osteosarcoma cells in vitro and reducing tumour burden in vivo [10,11]. This evidence concerns the gene TP53 and neoplasm.